Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

458
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
458
Chronic Pharyngitis01:23

Chronic Pharyngitis

7.7K
Chronic pharyngitis refers to persistent inflammation of the pharyngial mucosa.
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
7.7K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

793
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
793
Epistaxis01:30

Epistaxis

347
Epistaxis, or nosebleeds, occurs when small, swollen blood vessels in the nasal mucous membrane rupture. Typically, the anterior septum is the primary site of occurrence.
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
347
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

305
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
305
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

285
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
285

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic Corticosteroids in the Management of Sinonasal Disease: An Evidence-Based Expert Review.

International forum of allergy & rhinology·2026
Same author

Clinical Applications of Multimodal Artificial Intelligence in Otolaryngology: A State-of-the-Art Review.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2026
Same author

Beyond the scalpel: redefining surgical training for tomorrow: Canadian Conference for the Advancement of Surgical Education, Oct. 16-17, 2025 Winnipeg, Manitoba.

Canadian journal of surgery. Journal canadien de chirurgie·2026
Same author

Outcomes for Sinonasal Undifferentiated Carcinoma (SNUC): An International Multi-Center Retrospective Cohort Study.

Cancers·2026
Same author

Oral corticosteroid overexposure: characterizing oral corticosteroid use in patients with chronic rhinosinusitis with nasal polypS in Canada (ACTIONS) results.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2025
Same author

Utilizing a publicly accessible automated machine learning platform to enable diagnosis before tumor surgery.

Communications medicine·2025

Related Experiment Video

Updated: Nov 12, 2025

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

908

Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis.

Andrew Thamboo1, S Kilty2, I Witterick3

  • 1Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of British Columbia, 2600-1081 Burrard Street, Vancouver, British Columbia, V6Z 1Y6, Canada. andrew.thamboo@gmail.com.

Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'Oto-Rhino-Laryngologie Et De Chirurgie Cervico-Faciale
|March 22, 2021
PubMed
Summary
This summary is machine-generated.

Biologic therapies targeting Type 2 inflammation show promise for chronic rhinosinusitis with nasal polyposis (CRSwNP). This study provides Canadian guidance on using biologics for CRSwNP management, emphasizing individualized patient care.

Area of Science:

  • Immunology
  • Otolaryngology
  • Pharmacology
Keywords:
BiologicsChronic RhinosinusitisChronic rhinosinusitis with nasal polyposisType 2 inflammation

More Related Videos

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
06:08

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

2.1K
Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

2.7K

Related Experiment Videos

Last Updated: Nov 12, 2025

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

908
Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
06:08

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

2.1K
Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

2.7K

Background:

  • Biologic therapy targeting the Type 2 inflammatory pathway shows potential for improving chronic rhinosinusitis with nasal polyposis (CRSwNP).
  • A significant patient subset with CRSwNP experiences persistent symptoms despite conventional treatments, including medical therapy and endoscopic sinus surgery.
  • Monoclonal antibody agents, a class of biologics, represent a potential therapeutic option for these refractory CRSwNP cases.